REAC (Radio Electric Asymmetric Conveyer) represents an innovative medical technology platform designed for advanced neuromodulation and biomodulation applications. Unlike conventional techniques that impose stimuli through magnetic fields or direct current, REAC employs precisely calibrated, ultra-low intensity radioelectric fields transmitted asymmetrically and conveyed through specialized ACP (Asymmetric Conveyer Probe) devices. This sophisticated approach acts in a targeted manner by optimizing the organism's endogenous bioelectrical activity (EBA), promoting and supporting the body's intrinsic capacity to respond to disorders and pathologies.

Unlike other therapeutic modalities, REAC technology does not apply exogenous electrical currents to the organism, but rather modulates the endogenous bioelectrical fields of the human biological system. The organism's interaction with extremely low-intensity radioelectric fields, focused through the asymmetric conveyer probe, induces intratissular autologous microcurrents generated autonomously by the tissue itself. These appropriately modulated microcurrents contribute to the restoration of cellular bioelectrical homeostasis, optimizing intercellular communication mechanisms, reparative processes, and tissue regeneration phenomena. This methodological approach enables selective and targeted therapeutic action on specific cellular populations within the organism.

The fundamental difference lies in the mechanism:

• REAC vs. Electrotherapy/tDCS/CES: These techniques apply an exogenous (external) electric current to the body via electrodes. REAC, however, does not directly apply current but uses a radioelectric field to induce and modulate endogenous (internal) microcurrents through interaction with the body's bioelectric activity, focused by the asymmetric probe.

• REAC vs. TMS (Transcranial Magnetic Stimulation): TMS uses powerful, brief magnetic fields to induce significant electric currents in the brain, primarily superficially at the cortex, aiming to directly excite or inhibit neurons. REAC uses extremely low-intensity radioelectric fields, theoretically has no depth limitations, and aims to optimize existing bioelectric activity rather than inducing strong depolarization.

• Overall Goal: REAC aims to optimize and reorganize endogenous bioelectric functionality, whereas many other techniques aim to directly excite or inhibit neuronal activity by imposing an external stimulus.

Based on the numerous studies provided, REAC technology is considered safe, non-invasive, and painless. No significant or serious adverse effects have been reported in the presented studies.

REAC Technology® has demonstrated documented clinical efficacy across multiple pathological domains through the implementation of specific therapeutic protocols involving neuromodulation and biomodulation. The therapeutic applications encompass:

• Mood and behavioral disorders
• Chronic pain syndromes
• Postural and motor dysfunction
• Reparative and regenerative medicine interventions
• Inflammatory and metabolic pathologies
• Anti-aging applications

The REAC treatment is completely painless. Depending on the specific protocol administered, a probe (either point or planar) is applied to designated areas of the body. Patients typically experience no sensation during the applications.

Treatment session duration varies significantly according to the specific clinical protocol employed. Neuromodulation protocols, including preparation and administration phases, require only a few minutes of execution time. Up to four sessions may be performed within the same day, maintaining predetermined temporal intervals. Biomodulation protocols typically require longer application times while maintaining the feasibility of multiple daily administrations. The standard therapeutic cycle comprises an average of eighteen sessions. The possibility of multiple sessions per day enables treatment time optimization, providing temporal efficiency advantages for both healthcare practitioners and patients.

The numerous studies provided document the efficacy of various REAC protocols across diverse conditions. Efficacy has been measured through:

• Psychometric assessments (e.g., significant reductions in PSM, DASS-42, HAM-D, NPI scores).

• Clinical and functional evaluations (e.g., resolution of Functional Dysmetria, improved mobility, performance on motor tests like FTSST, TUG).

• Imaging studies (e.g., visible lesion healing via ultrasound or MRI, documented changes in brain activation patterns on fMRI).

• Quality of Life improvements (measured by validated questionnaires like SF-12, FIQ, PedsQL).

• Cellular studies (demonstrating effects like induction of neuronal differentiation and anti-senescence properties).
  Results frequently show statistically significant improvements compared to baseline or control groups (placebo or standard treatments where applicable).